Armata Pharmaceuticals, Inc. (NYSE: ARMP) is a clinical-stage biotechnology company focused on improving human health through the development of novel natural and synthetic bacteriophage-based therapies to treat multidrug-resistant bacterial infections and preventable infectious disease of the microbiome.
Antibiotic overuse has led to the marked rise of multidrug-resistant bacteria, putting us on the verge of a post-antibiotic era in which common infections can be serious or life-threatening. Additionally, the use of broad-spectrum antibiotics is known for disrupting the ecology of the human microbiome, leading to disease.
To combat the rapidly growing global problem of multidrug-resistant bacterial infections, Armata is utilizing two proprietary platforms – synthetic bacteriophage (phage) and peptides.